Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77


[Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes].

Manier S, de Charette de la Contrie M, Hieulle J, Daniel A, Facon T.

Presse Med. 2019 Jul - Aug;48(7-8 Pt 1):825-831. doi: 10.1016/j.lpm.2019.07.023. Epub 2019 Aug 22. French.


A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.

Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J.

Leukemia. 2019 Aug 19. doi: 10.1038/s41375-019-0539-0. [Epub ahead of print]


Current Situation of the Metabolomics Techniques Used for the Metabolism Studies of New Psychoactive Substances.

Manier SK, Meyer MR.

Ther Drug Monit. 2019 Aug 14. doi: 10.1097/FTD.0000000000000694. [Epub ahead of print]


Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2019 Aug 13. pii: mdz218. doi: 10.1093/annonc/mdz218. [Epub ahead of print] No abstract available.


Evaluation of novel organosilane modifications of paper spray mass spectrometry substrates for analyzing polar compounds.

Bambauer TP, Maurer HH, Weber AA, Hannig M, Pütz N, Koch M, Manier SK, Schneider M, Meyer MR.

Talanta. 2019 Nov 1;204:677-684. doi: 10.1016/j.talanta.2019.05.095. Epub 2019 May 26.


Use of UPLC-HRMS/MS for In Vitro and In Vivo Metabolite Identification of Three Methylphenidate-derived New Psychoactive Substances.

Manier SK, Niedermeier S, Schäper J, Meyer MR.

J Anal Toxicol. 2019 Jul 26. pii: bkz052. doi: 10.1093/jat/bkz052. [Epub ahead of print]


Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial.

Boyle EM, Leleu X, Petillon MO, Karlin L, Doyen C, Demarquette H, Royer B, Macro M, Moreau P, Fostier K, Marie-Lorraine C, Zarnitsky C, Perrot A, Herbaux C, Poulain S, Manier S, Beauvais D, Walker BA, Wardell CP, Vincent L, Frenzel L, Caillon H, Susanna S, Dejoie T, Avet-Loiseau H, Mohty M, Facon T; IFM2014-04 investigators.

Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16059. [Epub ahead of print]


Response to pneumococcal vaccination in multiple myeloma.

Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, Cayssials E, Bories C, Herbaux C, Systchenko T, Faucompré JL, Machet A, Sabirou F, Levy A, Bobin A, Richez V, Moya N, Gruchet C, Desmier D, van de Wyngaert Z, Carpentier B, Manier S, Facon T, Harding S, Leleu X.

Cancer Med. 2019 Jul;8(8):3822-3830. doi: 10.1002/cam4.2253. Epub 2019 May 30.


Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20. Review.


Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma.

Sahin I, Kawano Y, Sklavenitis-Pistofidis R, Moschetta M, Mishima Y, Manier S, Sacco A, Carrasco R, Fonseca R, Roccaro AM, Witzig T, Ghobrial IM.

Blood Adv. 2019 Apr 9;3(7):995-1002. doi: 10.1182/bloodadvances.2018028456.


Deregulation and Targeting of TP53 Pathway in Multiple Myeloma.

Jovanović KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S.

Front Oncol. 2019 Jan 9;8:665. doi: 10.3389/fonc.2018.00665. eCollection 2018. Review.


Antigen excess pitfall for free light chains measurements solved by ELISA assay.

Pekar JD, Schraen S, Grzych G, Manier S, Onraed B.

Am J Hematol. 2019 May;94(5):E120-E122. doi: 10.1002/ajh.25422. Epub 2019 Feb 6. No abstract available.


Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.

Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien ML, Leleu X, Hulin C, Manier S, Hébraud B, Roussel M, Do Souto L, Attal M, Avet-Loiseau H, Corre J.

Blood Adv. 2018 Nov 13;2(21):2811-2813. doi: 10.1182/bloodadvances.2018025197. No abstract available.


Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia.

Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M.

PLoS One. 2018 Oct 4;13(10):e0204589. doi: 10.1371/journal.pone.0204589. eCollection 2018.


Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche.

Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thrue CA, Nagano K, Petri A, Roccaro AM, Capelletti M, Baron R, Kauppinen S, Ghobrial IM.

Leukemia. 2018 Aug;32(8):1739-1750. doi: 10.1038/s41375-018-0161-6. Epub 2018 Jun 20.


A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.


Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.

Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM.

Nat Commun. 2018 Apr 27;9(1):1691. doi: 10.1038/s41467-018-04001-5.


Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

Supplemental Content

Loading ...
Support Center